Our Mission to End HIV

Developing a preventive vaccine for HIV is our top priority and we need armies of people to help make it happen. People in the sciences, people in clinical centers to execute these trials and volunteers—especially volunteers. I’m so impressed with the people who are helping move human health forward.

— Hanneke Schuitemaker, Ph.D., Vice President and Global Head of Viral Vaccine Discovery and Translational Medicine, Janssen Vaccines & Prevention B.V.

No single institution can tackle the historic challenge of eliminating an infectious disease. By advancing our technologies, uniting our best scientists and leveraging decades of experience in HIV, we’re optimistic that we can make a significant contribution to the global effort.

— Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer at Johnson & Johnson

Although HIV is now considered a chronic and manageable condition, the global challenge remains immense. With 37 million people around the world living with HIV —and nearly two million people newly-infected each year—we cannot treat ourselves out of the HIV epidemic. Our ultimate goal must be to find a preventive vaccine for HIV.

— Johan Van Hoof, M.D., Global Therapeutic Area Head, Vaccines, and Managing Director, Janssen Vaccines & Prevention B.V., Janssen Pharmaceutica NV

Over the last 10 years, Janssen has brought many new therapies to market with the aim to serve patients at all stages of diagnosis and treatment. These therapies have helped to transform the efficacy and tolerability of treatment and helped millions of patients around the world live healthier lives. We are proud of what has been achieved, and we will not stop here. At Janssen, we will continue to leverage our knowledge, science and expertise and partner with others to do more for people living with HIV.

— Brian Woodfall, M.D., Vice President, Global Head Late Development, Janssen Infectious Diseases & Vaccines

For decades, the Johnson & Johnson Foundation has partnered with local organizations to equip health workers with specialized training, education and novel technologies to support people living with HIV and help prevent future infections.

— Kris Sterkens, Company Group Chairman, EMEA, Janssen and Chair of the Johnson & Johnson Foundation